Your Main UNC2881-Rivals Does Not Want You To Study This Technique

Матеріал з HistoryPedia
Версія від 08:09, 11 червня 2017, створена Animal13neck (обговореннявнесок) (Створена сторінка: Compared with herpes simplex virus type 1 infection alone or transfection with negative control small interfering RNA, the viral titre and the retina epithelial...)

(різн.) ← Попередня версія • Поточна версія (різн.) • Новіша версія → (різн.)
Перейти до: навігація, пошук

Compared with herpes simplex virus type 1 infection alone or transfection with negative control small interfering RNA, the viral titre and the retina epithelial cell cytopathic effect were significantly decreased in retina epithelial cells transfected with infected-cell polypeptide 4-targeting small interfering RNA (50 and 100?nM) (P?Dinaciclib herpes simplex virus type 1 replication in retina epithelial cells, providing a foundation for development of RNA interference as an antiviral therapy. ""A/Prof Nitin Verma AM, Convenor Prof Paul McCartney Dr Michael Treplin Dr Guy Bylsma Dr Stephen Best Mrs Anu Verma Dr Asha Ram Dr Andrew Jones Dr Kristin Bell Ms Nell Treplin Ms Avril Cronk (RANZCO) Ms Sarah Stedman (RANZCO) Mr Phil Holmes (PCO) Prof Helen Danesh-Meyer (Chair) Dr Noel Alpins Dr Simon Dean Dr Shuan Dai A/Prof James Elder A/Prof Samantha Fraser-Bell Dr Tom Hardy Dr Phil House Dr Tony Kwan Dr Luke Maccheron Prof David Mackey Prof Charles McGhee Prof Bill Morgan Dr Andrew Symons A/Prof Nitin Verma AM Prof Stephanie Watson Dr Christine Younan Dr Stephen Best (Ex-officio) Prof Ted Maddess (Ex-officio) Ms Sarah Stedman (RANZCO) Ms Alexandra Terry (RANZCO) ""Although significant advances have been made in recent years in understanding the epidemiology of primary angle closure and primary angle-closure glaucoma, there is continued debate on the pathogenesis and optimal medical management of this condition. The way forward will be to embrace advances in anterior segment imaging, as this technology appears to hold promise to change our current management algorithms. Our present classification of this disease depends on clinical gonioscopic evaluation of the drainage angle, a skill that can be highly subjective and show significant interobserver variation.1 These limitations have fuelled the development of imaging devices that can achieve both objective and reproducible quantification of anterior segment dimensions resulting in an ability to accurately grade angle closure. In this issue, Friedman and colleagues provide a refreshing overview on both the current limitations we have in the diagnosis and management of primary angle-closure glaucoma and discuss new technologies and clinical trials that are on the horizon.